Identification of isoaspartate-modified transthyretin as potential target for selective immunotherapy of transthyretin amyloidosis-Reference-Cited by-同舟云学术

Identification of isoaspartate-modified transthyretin as potential target for selective immunotherapy of transthyretin amyloidosis

Published:2024-05-27 Issue:3 Volume:31 Page:184-194
ISSN:1350-6129
Container-title:Amyloid
language:en
Short-container-title:Amyloid

Author:

Köppen Janett¹,Kleinschmidt Martin¹,Morawski Markus²,Rahfeld Jens-Ulrich¹,Wermann Michael¹,Cynis Holger¹³,Hegenbart Ute⁴,Daniel Christoph⁵,Roßner Steffen²,Schilling Stephan¹⁶,Schulze Anja¹⁶

Affiliation:

1. Department of Drug Design and Target Validation, Fraunhofer Institute for Cell Therapy and Immunology, Halle (Saale), Germany

2. Paul Flechsig Institute – Center of Neuropathology and Brain Research, Leipzig, Germany

3. Faculty of Medicine, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany

4. Department of Hematology, Oncology and Rheumatology, Amyloidosis Center, University Hospital, Heidelberg, Germany

5. Department of Nephropathology, Friedrich-Alexander University Erlangen-Nürnberg (FAU), Erlangen, Germany

6. Faculty of Applied Biosciences and Bioprocess Technology, Anhalt University of Applied Sciences, Köthen, Germany

Funder

the Europäischer Fonds für regionale Entwicklung (EFRE) and Investitionsbank Sachsen-Anhalt

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/13506129.2024.2358121

Reference50 articles.

1. Treating Protein Misfolding Diseases: Therapeutic Successes Against Systemic Amyloidoses

2. Amyloidosis: diagnosis and new therapies for a misunderstood and misdiagnosed disease

3. Myocardial hypertrophy and function are related to age at onset in familial amyloidotic polyneuropathy

4. Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy

5. Transthyretin: the servant of many masters